Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/VRTX
icon
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $508.75, up 2.06% today, reflecting strong investor confidence amid a bullish technical signal. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, though recent quarterly EPS results were mixed. Positive Phase 2b data for its kidney disease drug inaxaplin, announced September 22, 2026, underscores its pipeline expansion beyond cystic fibrosis dominance.
Outlook remains positive with 84% analyst buy ratings and a $573.50 consensus target, implying 13% upside. Key risks include pipeline execution and reliance on cystic fibrosis treatments, but high profitability and expanding gene therapy initiatives support long-term growth potential for investors.
Read full analysis

Key Stats

  • Market Cap
    $128.95B
  • Volume
    2,239,249
  • Sector
    Health
  • 52W High
    $557.96
  • 52W Low
    $408.74
  • Typical Hold Time
    121 Days
  • Enterprise Value
    $123.07B
  • Div Yield
    -
  • Trading Activity
    5% Sell | 95% Buy
$499.74
52W Low: $408.74
16 Oct 2025
52W High: $557.96
03 Sep 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $408.74 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

Changan signs European partnerships and launches local service program to boost market presence

At the 2026 Mondial de l’Auto, Changan Automobile signed letters of intent with eight companies across seven European markets and launched its "with U" service program. This marks a strategic move to build a strong local ecosystem combining manufactu...

Market News
4 hours ago
Globe Newswire
Bullish
news icon
Changan signs European partnerships and launches local service program to boost market presence

Changan strengthens European presence with new partnerships and local service launch

Changan Automobile announced new partnerships covering seven European markets and launched its "with U" service program at Mondial de l’Auto 2026. This marks a shift from market entry to building a local ecosystem including manufacturing, sales, serv...

Market News
4 hours ago
Na
Bullish
news icon
Changan strengthens European presence with new partnerships and local service launch

Biotech IPOs and inverse ETFs lead market gains with strong debut and leveraged moves.

Recent biotech IPOs Iambic Therapeutics and City Therapeutics saw significant price jumps, rising 25.9% and 22.2% respectively after their market debuts, raising substantial capital. Inverse leveraged ETFs SMCZ and SMST also gained sharply as their u...

Market News
4 hours ago
Alex Lavoie
Bullish
news icon
Biotech IPOs and inverse ETFs lead market gains with strong debut and leveraged moves.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $128.95B
  • Volume
    2,239,249
  • Sector
    Health
  • 52W High
    $557.96
  • 52W Low
    $408.74
  • Typical Hold Time
    121 Days
  • Enterprise Value
    $123.07B
  • Div Yield
    -
  • Trading Activity
    5% Sell | 95% Buy
$499.74
52W Low: $408.74
16 Oct 2025
52W High: $557.96
03 Sep 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $408.74 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!